Armstrong Fleming & Moore’s Biogen BIIB Stock Holding History

Armstrong Fleming & Moore’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,733	Closed	-$374K	–	95
2024 Q1	$374K	Hold	1,733	–	–	0.26%	69
2023 Q4	$449K	Hold	1,733	–	–	0.34%	58
2023 Q3	$446K	Hold	1,733	–	–	0.43%	51
2023 Q2	$494K	Buy	+1,733	New	+$516K	0.45%	51

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armstrong Fleming & Moore's BIIB Position: Q2 2024 in Review

Armstrong Fleming & Moore sold out of Biogen (BIIB) in Q2 2024, closing a stake of 1,733 shares — an estimated $374K sold.

Armstrong Fleming & Moore first reported a position in BIIB in Q2 2023 and held it in 4 quarters. The position peaked at $494K in Q2 2023. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Armstrong Fleming & Moore reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Armstrong Fleming & Moore sold 1,733 Biogen shares in Q2 2024, an estimated $374K.
Armstrong Fleming & Moore first reported a position in Biogen in Q2 2023 and held it in 4 quarters.
Armstrong Fleming & Moore's Biogen position peaked at $494K in Q2 2023.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2024, filed 23 Jul 2024.